ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in an angel financing round, solely backed by RedHill Capital. The company is self-described as the first domestic cell therapy company utilizing induced pluripotent stem cells (iPSCs) technology to treat demyelinating diseases.
Demyelinating Diseases and Treatment Landscape
Neuro demyelinating diseases are a group of diseases characterized by destruction, disintegration, and loss of myelin sheath in the nervous system, including spinal cord injury, multiple sclerosis, Guillain Barre syndrome, and neuromyelitis optica, which affect tens of millions of patients in China. Traditional small molecules and antibody drugs have little effect on demyelination-related diseases.-Fineline Info & Tech
